Cognitive processes of apathy in Huntington's disease show high sensitivity to disease progression.
Clin Park Relat Disord
; 7: 100168, 2022.
Article
en En
| MEDLINE
| ID: mdl-36405870
ABSTRACT
Background:
Disease-modifying treatments for Huntington's disease (HD) are entering clinical trials there is a pressing need for objective outcome measures of disease progression. Our previous work showed an association between 2 novel, objective cognitive tasks and apathy - a core feature of disease progression in HD.Objective:
Evaluate the longitudinal validity and sensitivity of the novel Persistence and Maze tasks to assess their utility as clinical outcome measures in HD.Methods:
83 participants positive for the HD gene and 54 controls performed a battery of established and novel tools, at baseline and 12â¯month follow up.Results:
The Maze task was found to be the most sensitive measure of change at 12â¯months, including the current gold-standard measure (the composite disease progression score).Conclusion:
The Maze task has potential as a novel outcome measure of disease progression in HD and may have utility in other major neurodegenerative diseases.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Diagnostic_studies
Idioma:
En
Revista:
Clin Park Relat Disord
Año:
2022
Tipo del documento:
Article
País de afiliación:
Reino Unido